CONNECT WITH US
HealthTech

HealthTech

Oura makes bet on AI in healthcare with $625M Counsel Health buy

Healthcare Dive logo

Published on

Add as a preferred source on Google
Oura makes bet on AI in healthcare with $625M Counsel Health buy

Oura makes bet on AI in healthcare with $625M Counsel Health buy

The planned acquisition comes as wearable firms push to up their healthcare offerings.

Smart ring-maker Oura plans to acquire Counsel Health, which makes a platform where people can message an AI chatbot and a physician about their symptoms. Courtesy of Ōura

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback .

Oura said Tuesday it plans to buy artificial intelligence-based primary care company Counsel Health for $625 million in cash.

Counsel makes a service where people can message an AI chatbot about their symptoms and add a human physician to the conversation. Oura said it plans to pair the platform with biometric data from its smart rings.

Oura is making the acquisition as it adds more health features and partners with medtech firms such as Resmed and Dexcom.

Oura plans to offer Counsel’s platform within the Oura app. The pairing with Oura can give physicians context, biometric data and member engagement, Counsel CEO and founder Dr. Muthu Alagappan said in a statement.

Counsel’s platform uses AI agents to take a person’s medical history, retrieve guidelines, review records and detect emergencies. Users start by chatting with the AI, which provides guidance based on this information, prior interactions and biometric data. Patients can choose to add a physician to the chat, who can provide a diagnosis, prescriptions or referrals as appropriate.

Oura expects to close the acquisition before the end of the year.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.